Glancy Prongay & Murray Commences Investigation on Behalf of AngioDynamics Inc. Investors

Glancy Prongay & Murray LLP (“GPM”) is investigating potential claims on behalf of investors of AngioDynamics Inc. (“AngioDynamics” or the “Company”) (Nasdaq: ANGO) concerning the Company’s and its officers’ possible violations of federal securities laws.

AngioDynamics is a provider of minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. The investigation relates to the Company’s alleged misleading statements regarding its financial performance, and investor losses related to recent Company disclosures. On October 8, 2015, after the market closed, the Company announced poor first quarter, 2016 fiscal year financial results. The Company attributed the results to “negative year-over-year revenue growth due to tough comparisons to the prior year brought on by fiscal 2015’s voluntary withdrawal of our Morpheus PICC line and foreign currency headwinds.”

On this news, shares of AngioDynamics fell $0.88, or 7.1%, to close at $12.23 per share on October 9, 2015, thereby injuring investors.

If you purchased AngioDynamics securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151106005747/en/